PureTech Health (PRTC) announced the publication of new research in BMC Pulmonary Medicine that provides a view into the lived experiences of people with idiopathic pulmonary fibrosis. The study identifies critical barriers to treatment, opportunities for improved community engagement, and the need for patient-centered approaches in the development of new therapeutics. Initial findings from this research were presented at the 2023 Pulmonary Fibrosis Foundation Summit, the American Thoracic Society 2024 International Conference, and the CHEST 2024 Annual Meeting.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- Optimistic Buy Rating on PureTech Health Driven by Promising LYT-100 Developments and Strategic Growth Plans
- PureTech Health Reports Strong 2024 Financial Results
- PureTech Health confirms discussions with Nordic Capital Epsilon SCA
- PureTech Health plc – American Depositary Shares trading resumes
- PureTech Health plc – American Depositary Shares trading halted, volatility trading pause